Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

Conditions

• Cannabinoid Hyperemesis Syndrome

Eligibility Criteria

Sex

ALL

Age

18 Years - 100 Years

Healthy Volunteers

Not accepted

Interventions

• Olanzapine 10 milligram — DRUG
  olanzapine 10 mg IM
• Haloperidol — DRUG
  Haloperidol 5 mg IM

Study Details

The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.

Key Dates

Start date

Nov 6, 2025

Status verified

Nov 2025

Primary completion

Oct 31, 2026

Completion

Nov 30, 2026

Study Design

Enrollment

114 participants (estimated)

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Active Comparator: Haloperidol arm
  haloperidol
• Active Comparator: Olanzapine arm
  olanzapine

Primary Outcome Measure

Nausea VAS scale [ Time Frame: Change from Baseline nausea before medication administration to 60-120 minutes after medication administration ]

Central Contacts

• Joseph Jabour, DO FACEP
  3303476487
  [email protected]
• Amanda Gutek
  [email protected]

Locations (1)

Find similar trials in Toledo, OH